SCHEMBL30296178

SCHEMBL30296178

Nc1cc(Cl)c(-c2ccc3nsnc3c2)cc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 3/20 0.42
TDO2 P48775 1/20 0.40
PTPN1 P18031 1/20 0.35
PTPN6 P29350 1/20 0.35
MAPT P10636 3/20 0.34
NPSR1 Q6W5P4 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
APAF1 O14727 1/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
THRB P10828 1/20 0.34
NR4A1 P22736 1/20 0.34
RECQL P46063 1/20 0.34
BLM P54132 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
EPHB4 P54760 2/20 0.34
MAP4K4 O95819 3/20 0.33
BACE1 P56817 2/20 0.33
AHR P35869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31207482 0.82 PTPN11 (0.42) PTPN11TDO2MAPTNPSR1MEN1
SCHEMBL30296284 0.79 TDO2 (0.40) TDO2MAPTALDH1A1EPHB4MAP4K4
SCHEMBL30296442 0.79 EPHB4 (0.34) EPHB4BACE1AHRPTGS1PTGS2
SCHEMBL30296324 0.79 TDO2 (0.42) TDO2
SCHEMBL30296624 0.73 BACE1 (0.33) BACE1AHRPTGS1PTGS2
SCHEMBL31207416 0.71 TRPV1 (0.40) MAPTMEN1KMT2AALDH1A1POLB
SCHEMBL31207413 0.71 TRPV1 (0.40) MAPTMEN1KMT2AALDH1A1POLB
SCHEMBL30296553 0.71 NPC1 (0.42) TDO2MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL26457501 0.71 NPC1 (0.42) TDO2MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL15690403 0.71 PTPN11 (0.56) PTPN11PTPN1PTPN6MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-11-07 US disclosed
EP-4419203-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-08-28 EP disclosed
CN-118451080-A Tricyclic GPR65 modulators 帕蒂奥斯治疗有限公司 2024-08-06 CN disclosed
WO-2023067322-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS GPR65, GPR3, NR1H2 PTPN11 1919/4885TDO2 2047/4885PTPN1 2721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.